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Abstract: Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or
antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate
cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared to the first-generation
AR inhibitors. The landmark Phase III AFFIRM trial demonstrated improved overall survival benefit compared to placebo in addition to
improvement in all tested parameters. Enzalutamide is currently being studied in several trials prechemotherapy and in earlier settings
of prostate cancer. This review will discuss the mechanism of action of enzalutamide, its pharmacokinetics, the preclinical and clinical
trials that led to its approval, the ongoing clinical trials, its safety and efficacy, as well as patterns of resistance, and discusses its place
in therapy within the context of several recently approved agents for mCRPC.
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Introduction

Prostate cancer in the United States is expected to
result in 239,000 cases in 2013 with a projected death
of 29,700.1 Growth, as well as differentiation of the
prostate gland, is largely dependent on androgens
such as testosterone and dihydrotestosterone. Upon
malignant transformation, prostate tumor growth
is also driven by androgen signaling. In the 1940s,
Huggins and Hodges2 first showed that the effects of
surgical orchiectomy could lead to prostate cancer
regression.2 Since that time, androgen suppression
therapy (AST), through the use of gonadotropinreleasing hormone (GnRH) agents (predominantly
agonists and until recently, antagonists), has become
the cornerstone of systemic treatment for metastatic
prostate cancer. While AST results in prostate-specific
antigen (PSA) responses in a majority of cases,
relapse almost invariably ensues. Higher post-AST
PSA levels predict recurrence, which signals expression of androgen-regulated genes.3 Relapse usually
occurs within 12 to 24 months, as demonstrated by
either rising PSA, radiologic worsening, or deterioration of disease-related symptoms.4 Disease at
this juncture has previously been considered to be
“androgen-independent,” or “hormone-refractory,”
or “hormone-resistant.” However, these terms are
both a misnomer and misleading, since androgen
receptor expression is almost never lost. Further evidence and observation has shown that in many cases,
the response to residual levels of androgens or other
circulating hormones in a particular patient could
be amplified due to one of several factors including
mutation of the androgen receptor (AR) and alteration in levels of cofactor proteins, and thus would
still be sensitive to further hormonal manipulation.5
Therefore, the term “castration-resistant” is now
widely accepted and preferred.
In 2004, docetaxel was the first approved agent
showing a survival advantage in men with metastatic
castration-resistant prostate cancer (mCRPC) based on
the two pivotal trials, SWOG 9916 and TAX-327, both
of which demonstrated superior overall survival (OS)
outcomes in men treated with docetaxel and prednisone compared with mitoxantrone and prednisone in
the frontline setting,6,7 with updated results showing a
sustained survival advantage.8 During this subsequent
era, efforts have been made to search for varying
targets as well as combinations with docetaxel, with
236

the belief that once castration-resistance ensues, the
AR ceases to be a target.9 In June 2010, a novel taxane that was primarily studied in taxane-resistant
models, cabazitaxel, was approved in the second-line
setting based on the pivotal TROPIC trial.10 Several
recent studies in mCRPC have made it apparent that
prostate cancer growth remains dependent on androgen supply after the disease becomes unresponsive to
standard hormonal therapy.11 Based on these findings,
renewed interest in using new therapeutic agents
to target androgen-signaling for mCRPC patients
was seen. Abiraterone acetate, an inhibitor of cytochrome P450 17 (CYP17), in conjunction with prednisone, received approval in April 2011 for mCRPC
after docetaxel failure based on the COU-AA-301
trial.12 Almost in parallel, enzalutamide (formerly
MDV3100), an oral, second-generation AR inhibitor
that competitively inhibits androgen binding to the
AR and inhibits its nuclear translocation and interaction with deoxyribonucleic acid (DNA) was being
developed. This review describes the pharmacologic
parameters of this agent, its mechanism of action,
and the clinical trials that led to its approval by the
United States Food and Drug Administration (FDA),
its safety and efficacy, and discusses its place in the
proper sequencing treatment of prostate cancer.

Mechanism of Action, Metabolism
and Pharmacokinetic Profile
Mechanism of action

The AR is a 919-amino acid member of the steroid
receptor transcription factor superfamily with different
domains including an N-terminal regulation domain,
a central DNA binding domain, and a C-terminal
domain, which includes the ligand-binding domain
incorporated within its protein structure.13 Shortly
after the initial discovery of the AR in the late 1960s,
AR blockers have historically been included in the
backbone of prostate cancer therapy. AR inhibitors
serve as oral competitive inhibitors to endogenous
ligands to the AR that when bound, induces a conformational change that ultimately result in the transcription of AR-regulated genes. The initial steroidal
antiandrogens had significant progestational effects,
with compounds such as cyproterone acetate and
megestrol acetate. Nonsteroidal antiandrogens were
then developed and are more specific to the AR.14
Flutamide was discovered in the 1970s and was later
Clinical Medicine Insights: Oncology 2013:7
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approved for use in treating prostate cancer in 1989.
In 1995, bicalutamide was also approved and nilutamide followed a year later. In the 1980s, an approach
of complete androgen blockade (CAB) or maximal
androgen blockade, with a combination of antiandrogen antagonists and AST in an effort to eliminate or
block all testicular and adrenal sources of androgen,
was introduced.15 CAB garnered widespread support
at one time, but because of potential added costs and
toxicity in the setting of minimal added benefit,16 it
was not uniformly adopted in practice. In addition,
observations on the progression of use of peripheral
androgen blockade, as well as a phenomenon of clinical benefit upon discontinuation of antiandrogens has
led to the antiandrogen withdrawal syndrome, which
formed the basis to further understand androgen resistance since antiandrogens function as partial agonists
instead of antagonists.17 In addition, Sawyers et al18
found that this resistance may partly be due to upregulation in AR expression.18
The new AR antagonist, enzalutamide, soon represented the latest addition in the arsenal of secondary hormonal manipulating agents. Enzalutamide
was selected from a library of compounds for clinical
development, not only because of its favorable druglike properties19 and its effect on castration-resistant
prostate cancer (CRPC) xenograft models, but
also due to its ability to inhibit AR signaling in
the overexpression of AR cells with high binding
affinity to the AR and lack of agonist activity.20,21
Unlike previous antiandrogens, enzalutamide targets multiple steps in the androgen-signaling pathway (see Fig. 1). Enzalutamide bound to the AR in
a castration-resistant LNCaP/AR human prostate
cancer cell model demonstrated an eightfold greater
affinity than bicalutamide when evaluated using an
18-fluoro-deoxyglucose-dihydrotestosterone scan to
measure relative AR binding affinity in a competition
assay.20 In addition to an increased binding affinity
when bound to enzalutamide, the AR translocates
into the nucleus far less efficiently, and a significant
AR fraction remains in the cytosol. Enzalutamide
induces regression of established LNCaP/AR xenograft tumor cells, which overexpress ARs, growing
in castrated male mice. Bicalutamide treatment, on
the other hand, was shown to only retard growth.
Enzalutamide antagonized induction of PSA and
transmembrane serine protease 2, indicating a lack of
Clinical Medicine Insights: Oncology 2013:7
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Figure 1. Mechanism of action of enzalutamide. Enzalutamide has high
affinity for the androgen receptor (AR) and does not promote translocation of the AR to the nucleus and its binding to DNA, thus leading to
tumor death.

agonist activity. Regression seen with enzalutamide
is associated with continued evidence of apoptosis up
to 25 days after initiation of treatment.

Metabolism and pharmacokinetic profile

Based on the work done at Sawyers et al’s19 lab,
a nonsteroidal thiohydantoin agonist was selected as
the initial chemical framework due to its high affinity and selectivity for the AR. After 200 derivatives
were screened, the diarylthiohydantoin MDV3100 or
enzalutamide, was selected for further preclinical and
subsequently clinical studies.19 The pharmacokinetics of enzalutamide (formula C21H16F4N4O2S) and its
major metabolite, N-desmethyl enzalutamide, were
evaluated in patients with mCRPC and healthy male
volunteers. The plasma enzalutamide pharmacokinetics, in the studied dose range between 30 mg to 480 mg
given orally, exhibited a linear, two-compartmental
model with first-order absorption.22 Following
administration of one dose at 160 mg, enzalutamide
was absorbed rapidly in patients with mCRPC, with
median time to maximum plasma concentration of
1 hour, ranging between 30 minutes and 3 hours.
The terminal elimination half-life, in the same subset of patients following a single dose, was noted to
be 5.8 days with a range from 2.8 days to 10.2 days.
Plasma concentrations reached a steady state by day
28 of daily treatment and accumulated approximately
8.3-fold relative to a single dose, with low daily
fluctuations in plasma concentrations.
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In patients with mCRPC, the mean (%CV) predose Cmin or trough values for enzalutamide and
N-desmethyl enzalutamide were 11.4 (25.9%) µg/mL
and 13.0 (29.9%) µg/mL, respectively. The mean
apparent total plasma clearance of enzalutamide
was 0.56 L/hour (%CV: 29.9%).23 Enzalutamide was
found to be mainly metabolized by cytochrome P450
and more specifically, in vitro human CYP2C8 and
CYP3A4. CYP2C8 is responsible for the formation
of the active metabolite, N-desmethyl enzalutamide.
Following a single dose of 14C-enzalutamide 160 mg,
plasma samples were analyzed for enzalutamide and
its metabolites up to 77 days postdose. Enzalutamide,
N-desmethyl enzalutamide, and a major inactive
carboxylic acid metabolite accounted for 88% of the
14
C-radioactivity in plasma, representing 30%, 49%,
and 10%, respectively, of the total 14C-AUC0-inf.
Enzalutamide is excreted in the urine (71%) and
feces (14%) mainly as inactive metabolites. The
plasma pharmacokinetics of enzalutamide and
N-desmethyl enzalutamide were examined in volunteers with normal renal and hepatic function, as
well as those with mild (CrCl 60 to ,90 mL/minute)
and moderate (CrCl 30 to ,60 mL/minute) renal
impairment, as well as those with mild (Child Pugh
Class A) and moderate hepatic impairment (Child
Pugh Class B). The apparent clearance and composite area under the curve of enzalutamide was similar
in patients with preexisting mild and moderate renal
impairment, as well as in those with mild to moderate baseline hepatic impairment, respectively, compared to patients and volunteers with normal renal
and hepatic function; hence, there are no recommendations for initial dose adjustments or modifications for patients who have mild to moderate renal
or hepatic impairment.
The metabolism of enzalutamide may be modified by the concomitant administration of drugs
that are known inducers of CYP2C8 or CYP3A4.
However, no formal drug interaction studies have
evaluated the effect of specific inducers on enzalutamide pharmacokinetics. In vivo, the sum of enzalutamide and N-desmethyl enzalutamide exposure was
increased by 2.2-fold and 1.3-fold when it was coadministered with gemfibrozil (strong CYP2C8 inhibitor) or itraconazole (strong CYP3A4) inhibitor),
respectively, suggesting the need for avoidance of
such coadministration.23
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Clinical Studies: Preliminary
Studies/Clinical Studies

Given the important role of the AR in the pathogenesis of prostate cancer, inhibition of the AR in
addition to AST has been the subject of study in
metastatic prostate cancer. However, the earlier AR
inhibitors, bicalutamide and flutamide, demonstrated
no significant improvement in OS in patients with
hormone-sensitive metastatic prostate cancer.24–26
Certainly, limitations of the first-generation AR
inhibitors included their partial agonist activity in the
presence of overexpression of the AR.18 In addition,
compared to dihydrotestosterone, bicalutamide has a
lower affinity for the AR.27 In early preclinical trials,
enzalutamide showed a potency that was higher than
earlier generations of antiandrogens including flutamide, nilutamide, and bicalutamide.20 Enzalutamide
was found to have a ten-times greater affinity relative
to bicalutamide, and contrary to the latter, was shown
to be a pure antagonist to the AR. The encouraging
preclinical results led to the initiation of a Phase I/II
trial in humans.

Phase I/II study

In a Phase I/II trial assessing the efficacy and safety of
enzalutamide, 140 patients with CRPC were enrolled
at multiple centers to receive enzalutamide orally at
doses ranging from 30 mg to 600 mg daily.22 The vast
majority of the patients (78%) included in this trial
had metastatic disease. Around 44% of the patients
have not previously received treatment to the primary
tumor, whereas 30% have previously undergone surgery and 26% have previously received definitive
radiation therapy. Around half of the patients have
previously received chemotherapy and over 75% of
the patients have previously received at least two
lines of hormonal therapy. The maximum tolerated
dose was determined to be 240 mg daily, and there
was no additional benefit obtained from instituting
higher dosages. Antitumor activity was observed at
all tested dosages. The median time to radiological
progression was 47 weeks for all patients and it was
more prolonged in the chemotherapy-naïve group
(.60 weeks) than in the chemotherapy pretreated
group (29 weeks). Of the patients who had measurable disease, 22% had soft tissue response and of the
patients who had bone disease, 56% had stabilized
bone disease lasting 12 or more weeks. In addition,
Clinical Medicine Insights: Oncology 2013:7
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49% of the patients had conversion from unfavorable
(.5/7.5 mL) to favorable (,5/7.5 mL) circulating
tumor cell counts, indicating a favorable effect on this
adverse prognostic group of patients. The main side
effects included headache, hot flashes, and fatigue.
Fatigue was dose-dependent and occurred in 11% of
the patients. Three patients developed seizures and
those three patients were receiving the 360 mg dosage or higher, and two of the patients were on medications that lowered the seizure threshold. At longer
follow-up and at the time of updated analysis, 18 of
the enrolled patients remained in the study, with a
median time on therapy of 131 weeks.28 The median
time to PSA progression [as assessed by the Prostate
Cancer Working Group 2 (PCWG2)]29 was 41 weeks
and 20 weeks in the chemotherapy-naïve and the
chemotherapy-pretreated groups, respectively. The
median radiographic PFS was 56 weeks and 24 weeks
in the chemotherapy-naïve and the chemotherapypretreated group, respectively.

Phase III study: The AFFIRM study

Following the encouraging results of the Phase I/II
trial, the Phase III AFFIRM trial (A Study Evaluating
the Efficacy and Safety of the Investigational Drug
MDV3100) was designed. The AFFIRM trial was an
international double-blind placebo controlled trial in
men with mCRPC who have failed prior docetaxel-containing chemotherapy regimens.30 A total of 1,199 men
with mCRPC from 166 sites were randomized in a
2:1 manner to receive either enzalutamide 160 mg
daily (n = 800) or placebo (n = 399). Glucocorticoids
were not required, but were allowed and were seen in
about 30% of patients in both arms. The primary endpoint of the trial was OS. Secondary endpoints included
radiographic PFS, time to PSA progression, quality of
life, and time to the first skeletal-related event (SRE).
Patients were eligible to be enrolled in the trial if they
had progressed on prior chemotherapy which contained docetaxel, they had adequated organ function,
an Eastern Cooperative Oncology group (ECOG) performance status of 0–2. Around 50% of the patients in
both arms had received at least three prior lines of hormonal therapy, and 24% of the patients had received
two prior lines of therapy. An interim analysis was
planned after a total of 520 deaths had occurred.
In view of the improved OS favoring enzalutamide,
the study was unblinded at the recommendation of
Clinical Medicine Insights: Oncology 2013:7

the Data and Safety Monitoring Committee, and the
patients on placebo were allowed to cross-over to
receive enzalutamide. Despite this cross-over, after a
median follow-up of 14 months, the median OS was
significantly improved in the enzalutamide arm versus the placebo arm [18.4 months versus 13.6 months,
respectively; hazard ratio (HR), 0.63; 95% confidence
interval (CI), 0.53–0.75; P , 0.0001]. This 4.8-month
difference in OS translated in a 37% reduction in the risk
of death of any cause in the enzalutamide arm. A subgroup analysis showed that enzalutamide was superior to placebo, even in poor-risk categories including
those with lower hemoglobin, higher alkaline phosphatase, worse Eastern Cooperative Oncology Group
(ECOG) status, the presence of visceral disease, and
the presence of pain. The group of patients who did
not appear to benefit from enzalutamide was the one
that included patients who received two or more prior
chemotherapy regimens. Enzalutamide was superior
to placebo in all the examined secondary endpoints.
Enzalutamide was associated with improved time to
PSA progression by 5.3 months (8.3 months versus
3 months; HR, 0.25; P , 0.001) and improved median
radiographic PFS by 5.4 months (8.3 months versus
2.9 months; HR, 0.40; P , 0.001). Enzalutamide
also demonstrated a superior PSA response with at
least a 50% PSA reduction in 54% of the treated
patients compared with 1.5% in the placebo arm
(P , 0.001) and at least a 90% PSA reduction in 25%
of the treated patients compared to 1% in the placebo
arm (P , 0.001). Among patients who had measurable disease, Response Evaluation Criteria In Solid
Tumors overall response rates (ORRs) were 29% in
the enzalutamide arm compared to 4% in the placebo
arm (P , 0.0001). Enzalutamide also resulted in an
improvement in the time to first SRE (16.7 months versus 13.3 months; HR, 0.62; P , 0.0001) and quality
of life response rate as determined by the Functional
Assessment of Cancer Therapy-Prostate (FACT-P)
(43% versus 18%; P , 0.0001). There were also
beneficial effects on health-related quality of life, as
reported in an updated analysis.31 Pain palliation was
defined as .30% decline in the median pain score
after 12 weeks of treatment compared to pretreatment
pain score without a .30% increase in the use of
analgesics. Pain palliation was achieved in 45% and
7% of the patients in the enzalutamide and placebo
arms respectively (P = 0.008), and pain progression
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occurred in 28% of the patient on enzalutamide compared to 39% in the patients on placebo (P = 0.002).
Median time to pain progression on the FACT-P scale
was not reached for the enzalutamide arm compared
to 13.8 months for the placebo arm, thus representing a 44% risk reduction (HR, 0.56; P = 0.0004).
Interestingly a post hoc analysis showed that patients
who were taking corticosteroids at baseline in both
arms had inferior survival compared to those who
were not on steroids.32 In addition, on-study corticosteroid use was also associated with inferior OS and a
significantly worse side-effect profile compared to the
placebo group (grade 3–4 adverse events of 63.3% in
the corticosteroid cohort versus 34.4% in the noncorticosteroid cohort).33 One explanation could be that
the patients who had introduced steroids to their therapy might have had more severe disease at baseline.
This is evident also in the recent American Society of
Clinical Oncology (ASCO) presentation on the effect
of baseline corticosteroid use in men undergoing the
COU-AA-301 trial, which showed that while there is
a decline in the OS and a worse time to progression
on baseline corticosteroid use, this may be a mere
reflection of a preexisting, overall poorer prognostic risk of patients.34 Subsequent anticancer therapy
was common in both arms (41% of the enzalutamide
patients and 58% of the patients on placebo). The
most common posttrial therapies included abiraterone (21% and 24% in the enzalutamide and placebo
arms, respectively), cabazitaxel (10% and 14% in the
enzalutamide and placebo arms, respectively), docetaxel (9% and 14% in the enzalutamide and placebo
arms, respectively), and mitoxantrone (3% and 11%
in the enzalutamide and placebo arms, respectively).
On August 31, 2012, based on the overwhelming positive findings seen from the AFFIRM trial, the FDA
approved enzalutamide given at 160 mg daily for men
with mCRPC who had already received a docetaxelcontaining chemotherapy regimen.

median PSA response of 93% with a marked PSA
decline of −99.6%. In contrast to castration, there
was no change in the measured bone density or in
the measured metabolic variables such as body fat
mass, or glycemic and lipid profiles. The preliminary results of the Phase I study that evaluated the
combination of enzalutamide with docetaxel in the
chemotherapy-naïve mCRPC setting were also presented at the ASCO 2013 meeting.37 In that Phase I
trial, enzalutamide did not appear to alter tolerability
to docetaxel or affect its pharmacokinetics.37
A number of trials are currently underway to
evaluate the role of enzalutamide in a wide range of
patient populations and clinical settings. The safety of
the combination of the new novel agents, abiraterone
and enzalutamide, in mCRPC to the bones is being
studied in a Phase II trial (NCT01650194). In addition, a Phase III trial comparing abiraterone acetate to
abiraterone acetate with prednisone and enzalutamide
(Alliance A03121, funded through the Biomarker,
Imaging, and Quality of Life Studies Funding Program of the National Cancer Institute) seeks to enroll
1428 mCRPC chemotherapy-naïve patients with an
endpoint of OS. Two Phase II randomized trials are
comparing the combination of the PSA-TRICOM vaccine with enzalutamide to enzalutamide alone both in
the hormone-sensitive chemotherapy-naïve metastatic
setting and the nonmetastatic setting (NCT01867333
and NCT01875250). To ascertain whether enzalutamide would have a place in the prechemotherapy
setting, a Phase III randomized study of enzalutamide versus placebo in men with chemotherapynaïve mCRPC (PREVAIL study; NCT01212991) was
designed and has completed accrual with the results
eagerly awaited. Enzalutamide is being compared
to bicalutamide in the prechemotherapy setting in
two Phase II trials, both in the nonmetastatic and the
metastatic setting (NCT01288911, NCT01664923).
A selected list of these trials is shown in Table 1.

Recent and ongoing trials

Safety

A Phase II trial evaluated the role of enzalutamide
as monotherapy in hormone-naïve prostate cancer, and the results of the trial were reported at the
ASCO 2013 annual meeting.35,36 The trial included
67 patients, 39% of whom had metastatic disease, 36% had prior prostatectomy, and 24% had
radiation therapy. Enzalutamide achieved a high
240

Enzalutamide seems to be very well tolerated with a
favorable side effect profile. In the Phase I/II study,22
the most common grade 3–4 adverse event was dosedependent fatigue (11% of patients), which was only
observed at doses of 240 mg or greater, and generally
resolved after dose reduction. In this trial, the three
patients who developed seizures were receiving the
Clinical Medicine Insights: Oncology 2013:7
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A study to determine
safety and tolerability
of enzalutamide (MDV3100)
in combination with abiraterone
acetate in bone metastatic
castration-resistant prostate
cancer patients

Safety and efficacy study
of enzalutamide versus
bicalutamide in men with
prostate cancer (STRIVE)

A study of MDV3100 versus
bicalutamide in castrate
men with metastatic prostate
cancer (TERRAIN)

Study of MDV3100 as a
neoadjuvant therapy for
patients undergoing
prostatectomy for localized
prostate cancer

Enzalutamide with or without
vaccine therapy for advanced
prostate cancer

A study to test if MDV3100 is
effective and safe in prostate
cancer patients who have
never had hormone therapy

Enzalutamide in combination
with PSA-TRICOM in patients
with non-metastatic castration
sensitive prostate cancer

A phase 1b, open-label, safety
and tolerability study of oral
MDV3100 in combination
with docetaxel in men with
advanced prostate cancer

NCT01650194
(recruiting)

NCT01664923
(recruiting)

NCT01288911
(recruiting)

NCT01547299
(completed accrual)

NCT01867333
(recruiting)

NCT01302041
(completed accrualresults presented
at ASCO 2013)

NCT01875250
(recruiting)

NCT01565928
(completed accrualresults presented at
ASCO 2013)

Safety and
tolerability

Decrease
in tumor
regrowth rate

Proportion
of patients with
PSA response

Time to
progression

Pathological
complete
response rate

PFS

PFS

Nature, frequency
and severity of
adverse events

Primary endpoint

Phase Ib

Phase II
randomized

Phase II

Phase II
randomized

Phase II
randomized

Phase II
randomized

Phase II
randomized

Phase II

Phase

Abbreviations: PFS, Progression-Free Survival; mCRPC, metastatic Castration-Resistant Prostate Cancer.

Title of the study

Identifier
(status)

Chemotherapy
naïve mCRPC

Non-metastatic
prostate cancer,
hormone sensitive

Recurrent prostate
cancer, hormone
and chemotherapy
naive

Minimally symptomatic
chemotherapynaïve mCRPC with
progressive disease

Patients with
localized prostate
cancer undergoing
prostatectomy

mCRPC
chemotherapy-naïve

Recurrent prostate
cancer with disease
progression despite
androgen suppression
therapy (nonmetastatic patients
included)

Bone—mCRPC
who have received
no .2 prior
chemotherapy
regimen

Population

Table 1. Selected ongoing and recently completed trials of enzalutamide in patients with prostate cancer.

Enzalutamide + docetaxel

Enzalutamide + PSA
TRICOM versus
enzalutamide alone

Enzalutamide

Enzalutamide versus
enzalutamide + PSATRICOM

Neoadjuvant enzalutamide
versus enzalutamide +
leuprolide + dutasteride

Enzalutamide versus
bicalutamide

Enzalutamide versus
bicalutamide

Abiraterone +
enzalutamide

Treatment

Enzalutamide in prostate cancer
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360 mg dose or higher, and two of the patients were
on medications that lowered the seizure threshold.
In the AFFIRM study,30 there were few toxicities
that were more common in the enzalutamide arm,
and these included fatigue (all grades, 34% versus
29.1%), diarrhea, musculoskeletal pain, headache,
hypertension, and hot flashes. Overall, the enzalutamide group had a lower incidence of grade 3–4
adverse events (45.3% versus 53.1%). Enzalutamide
was also fairly well tolerated, with the most common
adverse reactions (occurring in .5% of patients)
including asthenia (34%), back pain, diarrhea (21%),
arthralgia, hot flashes (20%), peripheral edema, respiratory infection, muscular weakness, musculoskeletal
pain, headache (12%), dizziness, insomnia, upper or
lower respiratory infection, anxiety, hypertension,
spinal cord compression, cauda equina syndrome,
paresthesias, and hematuria, although a number of
these latter adverse events were perhaps secondary to
prostate cancer itself rather than medication-induced
side effects. Their incidence was equally present in
both the treatment and the placebo arms. Seizure
was reported in five patients in the enzalutamide arm
(versus none in the placebo arm) during the Phase III
trial with two further seizure events reported in the
follow-up data.23 However, certain risk factors for
lowering the threshold for seizure may have been
identified in these studies. Of the five patients who
experienced seizures, two had brain metastases, one
received lidocaine, and one patient had brain atrophy due to alcohol. There have been no reported seizures following discontinuation of enzalutamide. The
occurrence of seizure is postulated to be related to
the inhibition of γ-aminobutyric acid (GABA)-gated
chloride channels by enzalutamide. In the AFFIRM
study, patients with history of seizures or those who
were on medications that lowered the seizure threshold were excluded from the Phase III trial. Including
the two patients that experienced seizures in the longer follow-up of the AFFIRM study, the overall combined seizure risk was 1% (ten out of 940 patients).
As outlined in the pharmacokinetics section, several
drugs that are strong CYP2C8 inhibitors should be
avoided since increased plasma exposure to enzalutamide can be seen, as well as avoidance of strong
or moderate CYP3A4 or CYP2C8 inducers and substrates to CYP3A4, CYP2C9, and CYP2C19 with
narrow therapeutic indices.23
242

Efficacy

The efficacy of enzalutamide has been widely demonstrated by the AFFIRM trial.30 Although the Phase I/II
study showed that toxicity was significantly increased
at doses higher than 240 mg, there was no additional
benefit observed beyond the dose of 160 mg daily.
Therefore, the 160 mg daily dose was selected as the
optimal dosing regimen in the Phase III AFFIRM
study that formed the basis of FDA approval. The
Phase I/II study demonstrated that enzalutamide was
effective both in the chemotherapy-naïve and the
chemotherapy pretreated group. The AFFIRM study
included only patients postdocetaxel, and demonstrated that all endpoints including OS, radiographic
PFS, time to PSA progression, quality of life, pain
palliation, and time to the first SRE were improved
with enzalutamide. The anticipated results of the
PREVAIL study will ascertain whether enzalutamide
will play a role in the prechemotherapy setting and
will likely further change the therapeutic landscape
in prostate cancer.

Patient Preference

Since the approval of docetaxel in 2004, there are
now five agents that have shown to improve survival in mCRPC and these include sipuleucel-T,38
cabazitaxel,10 abiraterone,39 and radium 223,40 in
addition to enzalutamide. Enzalutamide is the second oral hormonal agent (after abiraterone) that can
extend survival in patients with mCRPC who were
previously treated with docetaxel. No direct comparison with abiraterone acetate is available. One advantage of enzalutamide over abiraterone is that it does
not require the coadministration of corticosteroids,
and thus be a better treatment option in the patient
population with comorbidities where corticosteroids
have the potential for significant side effects. On the
other hand, enzalutamide might not be suitable for
patients with a history of seizures or who are concurrently receiving medications that lower the seizure
threshold—a side effect not seen with abiraterone
use. However, there is currently no specific guidelines
or biomarkers that would predict the best sequence,41
timing, and specific population of patients that would
benefit from each of those agents. Several groups
have advocated for specific guidance on the use of
varying approved therapies that look mainly at symptoms, such as the American Urologic Association42
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and the National Cancer Comprehensive Network
(NCCN),43 though with the understanding that given
the rapidly evolving changes in the field, tailoring
treatment as the therapeutic landscape changes will
become appropriate as the literature changes.

Place in Therapy

The positive effects seen in the AFFIRM trial led
to the approval by the US FDA of enzalutamide in
the postchemotherapy setting. Currently, this is the
setting that has garnered widespread acceptance
in therap. However, results of the PREVAIL study
(which entailed enzalutamide given prior to chemotherapy) are eagerly awaited and may soon join the
ranks of abiraterone given prechemotherapy. The
exact role of the sequencing of these agents, or perhaps their use in combination, remains uncertain. The
aforementioned Alliance A03121 trial may further
inform the utility of the combination of abiraterone
acetate with enzalutamide versus abiraterone monotherapy in the prechemotherapypre-chemotherapy
mCRPC setting. Given the currently available literature, per the NCCN for instance, enzalutamide
has a category 1 recommendation postdocetaxel chemotherapy, but has a category 2A recommendation,
which equates to a consensus based on lower-level
evidence for docetaxel-naïve men.44 Furthermore,
varying studies are now looking at the utility of combining enzalutamide with a vaccine, or combination
with abiraterone, or using it in an earlier setting, as
has been shown in the enzalutamide monotherapy for
hormone-naïve prostate cancer.35,36
Concerns remain regarding the emergence of resistance, especially since resistance invariably occurs
with these agents. There are emerging retrospective data on the modest clinical activity observed, as
well as on the brief duration of responses with the
use of abiraterone after failure of prior docetaxel and
enzalutamide therapy.45,46 Given initial approval and
widespread use of abiraterone in 2011, and before
approval of enzalutamide in 2012, most patients who
would have received abiraterone and subsequently
switched to enzalutamide may not experience the
same benefit as was seen in the AFFIRM trial.41
Further analysis of the AFFIRM trial also shows that
in the subgroup analyses, men who had two or more
prior chemotherapy treatments did not do as well (with
HRs based on the nonstratified proportional hazards
Clinical Medicine Insights: Oncology 2013:7

model approaching 1), leading perhaps to consideration for earlier hierarchy in the sequencing.47 There
have been varying hypotheses on the mechanisms of
resistance,48 but cross-resistance conceivably be seen
with these agents as well. One such mechanism suggests that treatment with enzalutamide or abiraterone
leads to an adaptive shift towards an AR-splicevariant signaling, which gives rise to an increase in
the constitutively active AR-splice variants that lack
the AR-binding domain in prostate cancer.49 This is
further elucidated by restoration of responsiveness
to antiandrogens by knock-down experiments of
AR-V expression.50 Another potential mechanism
postulates an association with cellular Fas-associated
death domain-like interleukin 1β-converting enzyme
inhibitory protein expression, which plays a key role
in mediating therapeutic resistance and maintaining
viability of prostate cancer cells.51 A recent study that
highlights the development of cell lines that were
resistant to both enzalutamide and ARN-509, another
novel antiandrogen, showed that the presence of a
missense mutation (F876L) in the ligand-binding
domain of the AR conferred resistance to both compounds52 by converting to an AR agonist. Interestingly,
a molecular dynamics simulation performed led to a
chemical screen, which further identified additional
novel compounds that effectively antagonized AR
F876L to suppress the growth of prostate cancer cells
resistant to enzalutamide.53
Ultimately, the sequencing of these agents is of
paramount importance, as it enables patients to see
through all possible treatments that afford clinical
benefit and bring about survival. Currently, however, no biomarker exists that would reliably predict
responses to one agent over another, although enzalutamide would conceivably be effective even in the
setting of low levels of circulating androgens, while
higher levels of baseline-circulating androgens such as
testosterone and dehydroepiandrostenedione, as well
as ETS(erythroblast transformation specific)-related
gene rearrangements, may predict the likelihood of
response with abiraterone.54,55

Conclusion

The design, development, and approval of enzalutamide lend insights into one of the most anticipated successes in prostate cancer therapy. While the approval
of enzalutamide currently resides in the postdocetaxel
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space, there are promising reports of this drug being
used in an earlier setting and may soon change the
landscape of treatment for prostate cancer; however,
resistance to enzalutamide also inevitably occurs.
Thus, by improving the level of understanding of the
mechanisms of resistance, the potential for combination with other agents, and the use of this agent across
various settings of disease states in prostate cancer
have garnered wide research efforts in this field, and
will pave the way for better optimization of enzalutamide use in the treatment of prostate cancer.
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